Table 3 Discontinuation due to medication
Comparison | No. of participants (studies) | RR (95% CI) |
|---|---|---|
ZOL vs. Control | 665 (1 RCT) | 1.99 (0.76, 5.25) |
ALN vs. Control | 2750 (2 RCTs) | 0.88 (0.64, 1.22) |
RISE vs. Control | 2707 (3 RCTs) | 0.88 (0.69, 1.12) |
Etidronate vs. Control | 322 (3 RCTs) | 0.40 (0.03, 5.48) |
Ibandronate vs. Control | ||
 2.5 mg/d & 20 mg alternatively | 2929 (1 RCT) | 0.90 (0.69, 1.18) |
 0.5 mg & 1 mg per 3 months | 2860 (1 RCT) | 1.27 (0.97, 1.66) |
PTH vs. Control | 2215 (2 RCTs) | 1.54 (1.11, 2.13) |
 56.5 μg/w | 578 (1 RCT) | 1.80 (1.00, 3.24) |
 20 μg/d | 813 (1 RCT) | 1.10 (0.62, 1.95) |
 40 μg/d | 824 (1 RCT) | 1.82 (1.07, 3.10) |
Denosumab vs. Control | 956 (1 RCT) | 0.75 (0.44, 1.27) |
HRT vs. Control | 79 (2 RCTs) | 0.53 (0.17, 1.61) |
ALN vs. Denosumab | 717 (1 RCT) | 0.79 (0.15, 4.02) |
Romosozumab vs. Alendronate | 4093 (1 RCT) | 1.00 (0.58, 1.74) |
RISE vs. Teriparatide | 2070 (2 RCT) | 0.75 (0.57, 1.00) |
HRT vs. Etidronate | 35 (1 RCT) | 2.83 (0.33, 24.66) |